Emergent Biosolutions Inc (NYSE:EBS) Chairman Fuad El-Hibri sold 13,720 shares of Emergent Biosolutions stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $62.90, for a total value of $862,988.00. Following the completion of the sale, the chairman now directly owns 1,485,298 shares in the company, valued at $93,425,244.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Fuad El-Hibri also recently made the following trade(s):
- On Wednesday, February 5th, Fuad El-Hibri sold 48,316 shares of Emergent Biosolutions stock. The stock was sold at an average price of $60.66, for a total value of $2,930,848.56.
Shares of Emergent Biosolutions stock opened at $63.17 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.54 and a quick ratio of 1.71. The stock’s 50 day simple moving average is $56.76 and its 200-day simple moving average is $52.70. The stock has a market cap of $3.23 billion, a P/E ratio of 902.56, a P/E/G ratio of 0.88 and a beta of 1.53. Emergent Biosolutions Inc has a 1-year low of $39.11 and a 1-year high of $67.45.
Several research analysts recently commented on the company. TheStreet raised Emergent Biosolutions from a “c” rating to a “b” rating in a research note on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $75.00 target price on shares of Emergent Biosolutions in a research note on Friday, November 22nd. Chardan Capital reaffirmed a “buy” rating and set a $71.00 target price on shares of Emergent Biosolutions in a report on Thursday, November 7th. Wells Fargo & Co reiterated a “buy” rating on shares of Emergent Biosolutions in a research report on Thursday, November 7th. Finally, ValuEngine cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Thursday, November 14th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Emergent Biosolutions has a consensus rating of “Buy” and an average target price of $69.00.
Several large investors have recently bought and sold shares of the stock. Aigen Investment Management LP purchased a new stake in Emergent Biosolutions in the 4th quarter valued at about $32,000. Usca Ria LLC purchased a new position in Emergent Biosolutions during the third quarter worth about $35,000. Quadrant Capital Group LLC boosted its stake in Emergent Biosolutions by 1,510.2% during the third quarter. Quadrant Capital Group LLC now owns 789 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 740 shares during the period. Evoke Wealth LLC acquired a new stake in shares of Emergent Biosolutions during the third quarter valued at about $50,000. Finally, First Bank & Trust increased its position in shares of Emergent Biosolutions by 1,105.7% during the fourth quarter. First Bank & Trust now owns 1,049 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 962 shares during the last quarter. 86.10% of the stock is owned by hedge funds and other institutional investors.
About Emergent Biosolutions
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
Further Reading: How to build a Fibonacci channel
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.